Skip to main content


Bliss GVS Pharma extends gains
Bliss GVS Pharma rose 1.13% to Rs 468 at 10:27 IST on BSE, on bagging an order worth Rs 25 crore for supplying anti-malarial drugs for African countries.
The company made this announcement after the trading hours on Tuesday, 13 November 2007.
Meanwhile, BSE Sensex rose 517.56 points or 2.72% to 19,554.65, as worries about the US credit crisis eased after several top US executives reassured investors that the US banking system could withstand shocks from credit-related losses.
On BSE 580 shares were traded in the counter. The scrip had an average daily volume of 4,780 shares in the past one quarter.
The stock hit a high of Rs 480 and touched a low of Rs 453 so far during the day. The stock had a 52-week high of Rs 515 on 31 October 2007 and 52-week low of Rs 35.65 on 15 November 2006.
The small-cap scrip had outperformed the market over the past one month till 13 November 2007, gaining 17.81% compared to the Sensex's declining 0.12%. It had also outperformed the market in the past one quarter, gaining 135.68% compared to Sensex's rise of 26.90%.
The company's current equity is Rs 6.31 crore. Face value per share is Rs 10.
The current price of Rs 468 discounts Q2 September 2007 annualized EPS of Rs 77.46 by a PE multiple of 6.04. Bliss GVS Pharma's net profit rose 4788% to Rs 12.22 crore on 1894% growth in sales to Rs 29.91 crore in Q2 September 2007 over Q2 September 2006.
The company manufactures and distributes soft vaginal pessaries and anal suppositories. It operates in two segments, health care products and pharma products.

Best Regards,
Ramanathan N.S.

Popular posts from this blog

Bio-fuel has top investors powered up

23RD ,JUNE India's fortune-hunters believe their new-found love for biofuel will pay off. India's well-known investors who are known for their Midas touch have spotted an opportunity in bio-fuel, betting big on ethanol, bio-mass and even bio-fuel equipment makers in India and other parts of the globe. Billionaires Rakesh Jhunjhunwala, C Sivasankaran, Vinod Khosla, founder of Sun Microsystems, and Nemish Shah, the media-shy joint partner of Enam Financial Services, are investing in bio-fuel makers quietly, expecting that bio-fuel will have a big play in the coming years as the world looks for a viable alternative to the fast depleting oil reserves. Jhunjhunwala, who is known for his ability to spot a multi-bagger at a very early stage, recently invested in Hyderabad-based bio-fuel firm Nandan Biometrics.He is also a 10 per cent stakeholder in Praj Industries, which is a bio-fuel technology provider…

up to 8,500% return in 5 years! Investors made a killing in these 30 smallcap stocks

U By Rahul Oberoi, | Updated: Dec 01, 2017, 04.06 PM IST Post a Comment
Efficiency pays in the long run. Among the top smallcap plays on Dalal Street, 30 companies with stable return on equity (RoE) and return on capital employed (RoCE) have surged up to 8,500 per cent over the past five years.

All these companies had a debt-to-equity ratio of less than 1 and have been maintaining RoE and RoCE of over 20 per cent since 2012-13.

Avanti Feeds emerged the chart topper, with an 8,527 per cent gain to Rs 2,596.60 as of November 28 from Rs 30.10 ..

ovember 28 from Rs 30.10 on November 27, 2012. The company’s return on equity for FY17, FY16, FY15, FY14 and FY13 stood at 42.65 per cent, 46.21 per cent, 52.41 per cent, 45.79 per cent and 27.60 per cent, respectively. Avanti also managed to achieve a return on capital employed of over 50 per cent in last four years. Its RoCE stood at 28.59 per cent inRoE measures net income earned for every rupee of shareholder funds, while…

5 dark-horse picks

Kwadrat/ Kwadrat/
If you are a conservative investor, using the mutual fund route is the best way to invest in stocks. But if you are game for some excitement, you might want to dabble directly in stocks, especially small-cap stocks. Stocks that are smaller in size, in terms of market capitalisation, carry higher risk. The reasons are — one, lower traded volume increases price volatility, two, information is usually scarce on these companies, three, business risk is higher since many of these companies are dependent on a single product and four, governance risk is also higher in these stocks. That said, small-cap stocks have the capacity to deliver far greater returns when compared to large-cap stocks. Sample this: there were 16 stocks with market cap more than ₹50,000 crore in January 2009. These stocks delivered an average return of 138 per cent in the last eight years but 4 out of every 10 stocks in this group delivered negative returns. On the ot…